MedPath

Forward Pharma GmbH

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:2
Completed:5

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (33.3%)
Phase 2
1 (33.3%)
Phase 3
1 (33.3%)

Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis

Phase 3
Withdrawn
Conditions
Plaque Psoriasis
Interventions
Drug: FP187
Drug: Fumaderm® placebo
Drug: FP187 placebo
First Posted Date
2013-03-21
Last Posted Date
2016-08-09
Lead Sponsor
Forward-Pharma GmbH
Registration Number
NCT01815723
Locations
🇨🇦

Probity Medical Research, Waterloo, Ontario, Canada

Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis

Phase 2
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: FP187
Drug: Placebo
First Posted Date
2010-10-28
Last Posted Date
2012-12-11
Lead Sponsor
Forward-Pharma GmbH
Target Recruit Count
252
Registration Number
NCT01230138
Locations
🇩🇪

Dermatological Dept., Uniklinikum, TU-Dresden, Dresden, Germany

🇩🇪

SCIderm, Hamburg, Germany

News

No news found
© Copyright 2025. All Rights Reserved by MedPath